December 5-7th, 2017

Miami, FL


Workshop A
Thursday December 7th

09.00 - 12.00

Novel Approaches for Oncolytic Virus Combination Therapies

Workshop Leader: Samuel Rabkin, Professor of Neurosciences, Neurosurgery , Harvard Medical School

The field is in agreement that oncolytic viruses are likely to be most efficacious in combination therapies, alongside recent T-Vec phase 2 combination data and the immuno-oncology revolution there is a huge driver progressing rational oncolytic virus combinations.

Attend this session to discuss:

  • Combinations with immuno-oncology therapeutics
  • DNA Damage response and repair combinations
  • How combinations can modulate the TME for enhanced efficacy
  • What are the various different strategies and approaches for combinations
  • Preparing combination trials effectively in the clinic with the appropriate end points
  • Understanding the combination therapy’s mechanism of action

Leave this session with an understanding of the pros and cons of the various combination strategies and how they are playing out in the clinical setting.

Samuel Rabkin, Professor of Neurosciences, Neurosurgery , Harvard Medical School

Samuel D. Rabkin is the Thomas A. Pappas Professor in Neurosciences and Professor of Neurosurgery (Microbiology & Immunobiology) at Harvard Medical School, Boston MA, and Virologist in Neurosurgery at Massachusetts General Hospital, Boston, MA.  He is an Associate Editor of Molecular Therapy-Oncolytics.  After obtaining his PhD at the University of Chicago, he was an Assistant Member in Molecular Biology at Memorial Sloan-Kettering Cancer Center, New York, NY, and an Associate Professor in Neurosurgery at Georgetown University Medical Center, Washington DC.  Dr. Rabkin’s research has focused on the development of oncolytic herpes simplex viruses for cancer therapy.  He is an inventor on 14 US patents.

Workshop B
Thursday December 7th

13.00 - 16.00

Optimizing Oncolytic Viruses: Identifying the Right Viral Platform

Workshop Leader: Stephen Russell, CEO , Vyriad

Each and every oncolytic virotherapy program works on a different one of the many viruses that exist from HSV through to the coxsackie virus. But what is the optimum viral platform and do they
vary in their efficacies?

Attend this session to discuss:

  • How do you choose a viral platform successfully?
  • How can we begin to use the multitude of viruses available to target cancer?
  • Which is the “right” virus to use?
  • Does using a different virus result in different effects and what does this mean for the disease indication?
  • Are different viruses separate products?
  • Do the regulations need to vary when using different viruses?
  • Can you use different OVs sequentially to treat multiple tumors?

With so many potential unknowns, explore the landscape of different viral platforms and how each product can potentially be utilized for the best clinical efficacy.

Stephen Russell, CEO , Vyriad

Stephen J. Russell is currently the Richard O. Jacobson Professor of Molecular Medicine at Mayo Clinic in Rochester, Minnesota.  He obtained his M.B.Ch.B. from the University of Edinburgh, PhD. from University of London, and received specialist accreditation in Medicine and Haematology.  In 1998, he took the position of Director of the Molecular Medicine Program Mayo Clinic in Rochester, Minnesota and subsequently became Department Chair when the Program was converted to a department.


His research is focused on developing engineered viruses for the treatment of disseminated malignancies (particularly multiple myeloma) and demonstrating their efficacy in clinical trials.  Research themes in his laboratory include the engineering of viral membrane glycoproteins, targeting cell to cell fusion, targeting virus entry, using cellular microRNAs to reprogramme virus tropism, pharmacokinetic and pharmacodynamic studies of virus-based therapies, noninvasive monitoring and imaging of viral gene expression in vivo, and radiovirotherapy.  He is a practicing haematologist.